NCT03805984View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 9, 2019

Primary Completion Date

October 21, 2020

Study Completion Date

October 21, 2020

Conditions
Lassa Fever
Interventions
DRUG

INO-4500

INO-4500 will be administered ID on Day 0 and Week 4.

DRUG

Placebo

Placebo will be administered ID on Day 0 and Week 4.

DEVICE

CELLECTRA® 2000

EP using the CELLECTRA® 2000 device will be administered following ID drug administration.

Trial Locations (1)

64114

The Center for Pharmaceutical Research, Kansas City

Sponsors
All Listed Sponsors
collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

lead

Inovio Pharmaceuticals

INDUSTRY

NCT03805984 - Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers | Biotech Hunter | Biotech Hunter